nuclear mitotic apparatus protein 1Genealiases: NMP-22 · NUMA
Q-omics provides the consensus-scored NUMA1 profile across patient tissues and cancer cell-line models. NUMA1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NUMA1 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, NUMA1 protein abundance shows 22,608 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where NUMA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUMA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUMA1 survival associations across molecular data types. NUMA1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUMA1 RNA expression–survival associations across cancer types. High NUMA1 expression shows unfavorable associations in LIHC and ACC, but favorable associations in KIRC, BRCA, UCEC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for NUMA1 RNA expression.
This table summarizes NUMA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NUMA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUMA1 shows lower tumor expression in UCEC and KIRP and higher tumor expression in LIHC, CHOL, STAD and PRAD. The LIHC box plot shows higher NUMA1 RNA expression in tumor versus normal tissue (log2 FC = +1.041, t-test p < 0.001).
This table shows molecular features associated with NUMA1 in patient tissues and cancer cell lines. In patient samples, NUMA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUMA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
